In this blog, Dr John Pezaris explains the challenges facing the development of visual prostheses to enable recipients to see, and discusses some of the promising work being done to overcome these.
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor are a new preventive treatment for migraine, acting upon one of the molecules implied in the pathogenesis of migraine headache. The European Headache Federation has recently published their guideline on the use of these monoclonal antibodies for migraine prevention. We have invited junior headache researcher Raffaele Ornello to explain the main findings and why they are important.
[slickquiz id=26]